NCT05723835 - A Research Study Looking at How Safe Somapacitan is and How Well it Works in Children Who Need Help to Grow - REAL 9 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 1, 2023

Primary Completion Date

June 7, 2024

Study Completion Date

October 29, 2027

Conditions

SGATurner SyndromeNoonan SyndromeISS

Interventions

DRUG

Somapacitan

Somapacitan 0.24 milligrams per kilograms per week (mg/kg/week) will be administered subcutaneously (s.c.) using PDS290 pen-injector.

Trial Locations (17)

Univ of AL at Birmingham_BRM, Birmingham

University Technology MARA (UiTM) - Sg Buloh, Bandar Puncak Alam Selangor Darul Ehsan

Pusan National University Yangsan Hospital, Yangsan

Children's Minnesota, Saint Paul

University Malaya Medical Centre, Kuala Lumpur

Rocky Mt Ped and Endo, Centennial

Sutter Valley Med Fdt Ped Endo, Sacramento

Childrens National Medical Ctr, Washington D.C.

Rocky Mt Clin Res, LLC, Idaho Falls

Erasmus MC, Rotterdam

Kliniczny Szpital Wojewodzki nr 2 im. Sw. Jadwigi Krolowej w Rzeszowie, Rzeszów

UCK, Klinika Pediatrii, Diabetologii i Endokrynologii,, Gdansk

Instytut Centrum Zdrowia Matki Polki, Lodz

SPSK nr 1 im. prof.S.Szyszko w Zabrzu, Zabrze

Asan Medical Center, Seoul

Hospital Vall d'Hebron, Barcelona